Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Faculty of Medicine, Alexandria University, Alexandria, Egypt; International Medical Research Association (IMedRA), Egypt.
Indian Heart J. 2022 May-Jun;74(3):155-162. doi: 10.1016/j.ihj.2022.03.005. Epub 2022 Mar 15.
To assess the safety and efficacy of omecamtiv mecarbil compared with placebo in heart failure (HF) patients.
We searched PubMed, Web of Science, Cochrane Library, and SCOPUS until August 15th, 2021. We included all randomized controlled studies comparing omecamtiv mecarbil with placebo in heart failure patients. The meta-analysis was carried out using Rev Man software V5.4.
A total of eight studies were included in our systematic review. Pooled analysis showed that omecamtiv mecarbil is not associated with increased incidence of death, any adverse events, hypotension, heart failure, ventricular tachyarrhythmia, dyspnea, dizziness, and serious adverse events. Regarding the efficacy, omecamtiv mecarbil significantly reduced heart rate with some studies demonstrating its significant improvement in left ventricular ejection fraction and systolic function.
Omecamtiv mecarbil is a well-tolerated drug in heart failure patients. The limited data regarding the efficacy suggested that it may improve ejection fraction and systolic function.
评估 omecamtiv mecarbil 与安慰剂相比在心力衰竭（HF）患者中的安全性和疗效。
我们检索了 PubMed、Web of Science、Cochrane Library 和 SCOPUS，检索时间截至 2021 年 8 月 15 日。我们纳入了所有比较 omecamtiv mecarbil 与安慰剂在心力衰竭患者中的随机对照研究。使用 Rev Man 软件 V5.4 进行荟萃分析。
共有 8 项研究纳入我们的系统评价。汇总分析显示，omecamtiv mecarbil 与死亡率增加、任何不良事件、低血压、心力衰竭、室性心动过速、呼吸困难、头晕和严重不良事件无关。关于疗效，omecamtiv mecarbil 显著降低了心率，一些研究表明其对左心室射血分数和收缩功能有显著改善。
omecamtiv mecarbil 在心力衰竭患者中耐受性良好。关于疗效的有限数据表明，它可能改善射血分数和收缩功能。
